IMMUNE PHARMACEUTICALS INC
DelistedCIK 1208261fmd_1DK44YFR64AGQHPYB7MQ5BNKSEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2018, 35 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 1 | 8 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | – | 1 | 1 | 0 | – | – | – | – | – |
| Gross profit | – | (0) | 0 | 7 | – | – | – | – | – |
| Research and development | 12 | 8 | 8 | 4 | 4 | 6 | 6 | 8 | 6 |
| Selling, general and administrative | 8 | 7 | 6 | 5 | 5 | 11 | 10 | 6 | 7 |
| Operating income | (19) | (15) | (14) | (9) | (9) | (16) | (16) | (27) | (12) |
| Interest expense | 20 | 0 | 1 | 0 | 0 | 3 | 1 | 2 | 4 |
| Interest and investment income | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | (20) | (0) | (2) | – | – | (0) | (0) | (0) | (0) |
| Income before taxes | (39) | (16) | (16) | (13) | (6) | (24) | (17) | (38) | (20) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (5) | (2) |
| Net income from continuing operations | (39) | (16) | (16) | (13) | (6) | (24) | (17) | (33) | (18) |
| Net income | – | (1) | (2) | (13) | (6) | (24) | (17) | (33) | (18) |
| Net income to common shareholders | (39) | (16) | (16) | (13) | (7) | (24) | (24) | (41) | (25) |